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Functional Importance of Angiotensin-Converting
Enzyme–Dependent In Situ Angiotensin II Generation in
the Human Forearm
Jasper J. Saris, Marjan A. van Dijk, Ingrid Kroon, Maarten A.D.H. Schalekamp, A.H. Jan Danser
Abstract—To assess the importance for vasoconstriction of in situ angiotensin (Ang) II generation, as opposed to Ang II
delivery via the circulation, we determined forearm vasoconstriction in response to Ang I (0.1 to 10 ng z kg21 z min21)
and Ang II (0.1 to 5 ng z kg21 z min21) in 14 normotensive male volunteers (age 18 to 67 years). Changes in forearm
blood flow (FBF) were registered with venous occlusion plethysmography. Arterial and venous blood samples were
collected under steady-state conditions to quantify forearm fractional Ang I-to-II conversion. Ang I and II exerted the
same maximal effect (mean6SEM 7164% and 7564% decrease in FBF, respectively), with similar potencies (mean
EC50 [range] 5.6 [0.30 to 12.0] nmol/L for Ang I and 3.6 [0.37 to 7.1] nmol/L for Ang II). Forearm fractional Ang I-to-II
conversion was 36% (range 18% to 57%). The angiotensin-converting enzyme (ACE) inhibitor enalaprilat (80 ng z kg21 z
min21) inhibited the contractile effects of Ang I and reduced fractional conversion to 1% (0.1% to 8%), thereby
excluding a role for Ang I-to-II converting enzymes other than ACE (eg, chymase). The Ang II type 1 receptor
antagonist losartan (3 mg z kg21 z min21) inhibited the vasoconstrictor effects of Ang II. In conclusion, the similar
potencies of Ang I and II in the forearm, combined with the fact that only one third of arterially delivered Ang I is
converted to Ang II, suggest that in situ–generated Ang II is more important for vasoconstriction than circulating Ang
II. Local Ang II generation in the forearm depends on ACE exclusively and results in vasoconstriction via Ang II type
1 receptors. (Hypertension. 2000;35:764-768.)
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Circulating angiotensin (Ang) I is converted to Ang II inmany vascular beds.1–5 The functional importance of this
locally generated Ang II compared with arterially delivered
Ang II is currently unknown. Organ bath experiments in
which the contractile responses of isolated human or porcine
coronary arteries were recorded have shown that Ang I and
Ang II display similar vasoconstrictor potencies,6,7 despite
the fact that the levels of Ang II in the bath fluid during
exposure to Ang I are ,1% of those during exposure to Ang
II.6 These in vitro experiments therefore suggest that locally
generated rather than circulating Ang II mediates vasocon-
striction. A study of the local generation of Ang II and its
vasoconstrictor effects in perfused rat hindquarters, in which
the venous Ang II levels after the infusion of renin were
compared with those after the infusion of Ang I or II, also
indicated that vasoconstriction was caused by local Ang II
rather than by Ang II in the perfusion buffer.8
Two enzymes have been reported to contribute to Ang
I-to-II conversion: ACE and chymase. ACE is present both in
circulating blood plasma and on the membrane of vascular
endothelial cells, whereas chymase is located in the adventi-
tia, in the cytosol of mast cells.9,10 Although the results of in
vitro studies in isolated human vessels6,7 and tissue homog-
enates11,12 support the contribution of chymase to Ang I-to-II
conversion, in vivo studies do not support this view, because
ACE inhibition suppressed Ang I-to-II conversion in the
human and porcine coronary vascular beds by .90%.3,13
However, coronary Ang I-to-II conversion in these latter
studies was quantified with systemic or intracoronary infu-
sions of 125I-labeled Ang I, an approach that does not allow
the detection of Ang II generation with chymase in the
adventitia if such generation does not result in Ang II
overflow into the blood compartment. Moreover, contractile
effects were not quantified in these studies.
It was the aim of the present study to compare the in vivo
potencies of Ang I and II to assess the functional importance
of locally generated Ang II. Ang I and Ang II were infused
into the brachial artery, and forearm vasoconstriction was
recorded under steady state conditions. Forearm Ang I-to-II
conversion was quantified with measurment of the venous
Ang I and II levels at steady state. Infusions were made in the
presence and absence of the ACE inhibitor enalaprilat and the
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Ang II type 1 (AT1) receptor antagonist losartan to investigate
(1) whether enzymes other than ACE contribute to the local
generation of Ang II and (2) whether Ang II mediates




Fourteen white male volunteers (mean age 39 years, range 18 to 67
years; mean weight 83 kg, range 64 to 107 kg) were recruited via
advertisement after the Medical Ethics Committee of the Leiden
University Medical Center approved the protocol of the study. All
participants gave their informed consent. Medical history, physical
examination, and routine laboratory tests did not reveal any abnor-
malities. All subjects were on a normal-sodium diet (’180 mmol/d),
and none of them received medication. Subjects did not smoke, and
they refrained from the consumption of alcohol or caffeine-
containing substances for $12 hours before the experiment.
Experimental Set-Up
Each experiment was performed with the subject in the supine
position in a quiet room at a constant temperature of 22° to 24°C.
Forearm and hand volumes were measured with water displacement.
One-lead ECG was monitored continuously. After local anesthesia
with 1% lidocaine, the brachial artery of the nondominant arm was
cannulated. The cannula (1.0345 mm) was connected to a Statham
P23Id pressure transducer (Gould Inc). Drugs were infused into the
brachial artery with Harvard Apparatus volumetric precision pumps
(model 22). Both forearms were instrumented with mercury-in-
Silastic strain gauges, which were connected to a Hokanson EC-2
plethysmograph. Both upper arms were connected to a Hokanson
E-10 rapid cuff inflator. For the measurement of forearm blood flow
(FBF), R wave–triggered cuff inflation (at 40 mm Hg) for venous
occlusion plethysmography was controlled with a personal comput-
er.14 FBF was measured 4 times per minute, and the final 6
measurements at the end of each dose step, when a steady state had
been reached,15 were used for further analysis. During each infusion
experiment, the hands were continuously excluded from the circu-
lation with the inflation of small wrist cuffs to a minimum of
40 mm Hg above systolic blood pressure. Heart rate from the ECG,
intra-arterial blood pressure, and left and right FBF values were
recorded on a polygraph (Gould Inc) and on a personal computer
with an analog-to-digital converter (model DT 2801; Data Transla-
tion Inc).
Study Protocol
The infusion studies were started $60 minutes after the cannulation
of the brachial artery. Between the various infusion experiments, the
wrist cuffs were deflated, and sufficient time (minimum of 45
minutes) was taken to allow the subjects to recover from hand
ischemia and to allow FBF to return to baseline levels. The protocol
is summarized in Figure 1. Baseline arterial and venous blood
samples were taken before the start of the infusions. Steady-state
venous blood samples were obtained at the end of each Ang infusion.
Sodium nitroprusside was used to predilate the vascular bed of the
forearm to ’5 mL z 100 mL21 z min21 because measurements of
vasoconstrictor effects are more accurate when flow levels remain at
.1 mL z 100 mL21 z min21.16
Blood Sampling
Blood for Ang measurements was rapidly drawn with a plastic
syringe containing the following inhibitors (0.25 mL inhibitor
solution in 5 mL blood): 6.25 mmol/L disodium EDTA,
1.25 mmol/L 1,10-phenanthroline, and 0.01 mmol/L concentration
of the renin inhibitor remikiren (final concentrations in blood). The
blood was transferred into prechilled polystyrene tubes and centri-
fuged at 3000g for 10 minutes at 4°C. Plasma was stored at 270°C.
Measurement of Ang I and II
Baseline arterial and venous Ang I and II concentrations were
measured with radioimmunoassay, after SepPak extraction and
high-performance liquid chromatographic separation, as described
previously.2,3 The high Ang concentrations in the venous samples
collected under steady state conditions at the end of each infusion
were measured without prior high-performance liquid chromato-
graphic separation.6
Data Analysis
Data were normally distributed and are expressed as mean6SEM. The
Ang-induced effects are expressed as percentage change in FBF of the
infused forearm. The percentage change was calculated relative to the
values measured at baseline (ie, at the beginning of infusion 3) (Figure
1). The steady state arterial Ang plasma concentrations (in pmol/L)
during the infusions were calculated as follows: [Ang]art, steady state5
IR3BW3106/[(12Ht)3FBF3FAV3MW]1[Ang]art, baseline, where IR
is Ang I or II infusion rate (in ng z kg21 z min21), BW is body weight (in
kg), Ht is hematocrit, FAV is forearm volume, MW is molecular weight
of Ang I or II, and [Ang]art, baseline is arterial Ang I or II concentration at
baseline.
Fractional conversion and degradation of Ang I (ie, the percentage
of arterially delivered Ang I that is converted to Ang II or degraded
into other metabolites) and fractional degradation of Ang II (ie, the
Figure 1. Schematic presentation of infu-
sion experiments. Top, Intra-arterial infu-
sion protocol. In experiments 2 and 4,
continuous infusion 2 was started 3 min-
utes after start of continuous infusion 1.
In all experiments, infusion 3 was started
5 minutes after start of infusion 1; infu-
sion 3 consisted of 3 dose steps that
lasted 5 minutes each. Blood sampling
(BS) occurred under baseline conditions,
before start of infusions, and at end of
each dose step of infusion 3, when a
steady state had been reached. Bottom,
infusion rates in ng z kg21 z min21. SNP
indicates sodium nitroprusside; Ang, an-
giotensin; enal, enalaprilat; and los,
losartan.
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percentage of arterially delivered Ang II that is degraded) in the
forearm were calculated as described previously.2,3
EC50 values (ie, the arterial Ang I or II concentration at which 50%
of the maximal effect is achieved) were calculated from the arterial
plasma concentrations and the corresponding FBF values with
4-parameter logistic regression analysis (InPlot 2.0; GraphPAD
Software).15,17
Student’s t test and ANOVA for repeated measures were used for
statistical evaluation. Values of P,0.05 were considered statistically
significant.
Results
Baseline arterial Ang I and II levels (6.960.6 and 2.760.2
fmol/mL, respectively) were comparable to baseline venous
Ang I and II levels (10.862.3 and 3.060.2 fmol/mL, respec-
tively). Baseline Ang levels were unrelated to age or weight.
FBF did not change in the noninfused control arm during
the infusions, nor did the Ang infusions affect heart rate and
blood pressure (data not shown).
Ang I and II reduced FBF by a maximum of 7164% and
7564%, respectively, with comparable potencies (EC50
5.661.0 and 3.660.5 nmol/L, respectively; P5NS) (Figure
2). Enalaprilat virtually completely blocked the constrictor
effects of Ang I. Losartan blocked the vasoconstrictor effects
of Ang II; in fact, a tendency for a vasodilator effect (P5NS)
was observed at the 2 lowest doses of Ang II in the presence
of this drug.
Fractional Ang I conversion was similar at all Ang I doses
and was reduced to very low values in the presence of
enalaprilat (Table). Fractional Ang I and II degradations were
higher at the high doses than at the low doses of these
peptides, most likely because of the reduced FBF at these
high doses. In support of this assumption, FBF correlated
negatively with fractional Ang I and II degradation (fractional
Ang I degradation520.063FBF10.69 [r50.56, P,0.05]
and fractional Ang II degradation520.063FBF10.97
[r50.76, P,0.01]). The relationship between FBF and Ang
degradation was unaltered with enalaprilat and losartan (data
not shown).
Discussion
The results of the present study provide in vivo evidence in
humans that in situ–generated Ang II is more important for
vasoconstriction than circulating Ang II. This conclusion is
based on 2 findings. First, Ang I and Ang II induced forearm
vasoconstriction with similar potencies, despite the fact that
only one third of Ang I was converted to Ang II in the
forearm circulation. Second, the venous Ang II levels at the
highest Ang I infusion rate in the presence of enalaprilat were
comparable to the venous Ang II levels at a 50-fold lower
Figure 2. Percent change of forearm blood flow (FBF) in
response to Ang I without (E) or with (F) enalaprilat and to Ang
II without (M) or with (f) losartan. Data are mean6SEM of 14
experiments.
Venous Angiotensin Levels, Fractional Ang I Conversion, and Fractional Ang I and II
Degradation During Infusion of Ang I or II With or Without Concomitant Infusion of ACE
Inhibitor Enalaprilat (80 ng z kg21 z min21) or AT1 Receptor Antagonist Losartan
(3000 ng z kg21 z min21)
Parameter
Infusion Rate, ng z kg21 z min21
Ang I Ang I1Enalaprilat
0.1 1.0 10 0.5 5.0 50
Ang I, pmol/L 4366 304656 16916334 5836108 658361029 46 16166243
Ang II, pmol/L 7065 544696 530761037 2965 103630 6626193
Fractional Ang I
conversion, %
4163 3263 3462 261† 161† 160†
Fractional Ang I
degradation, %
4862 6262* 6462* 3867 4868 6865*
Ang II Ang II1Losartan
0.1 0.5 5.0 0.1 0.5 5.0
Ang II, pmol/L 97610 458666 42836627 9767 443662 37436498
Fractional Ang II
degradation, %
6464 7863* 8863* 4864 5864 7663*
Data are mean6SEM (n514).
*P,0.01 vs lowest infusion rate.
†P,0.001 vs without enalaprilat.
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Ang I infusion rate without enalaprilat, yet vasoconstriction
was observed only in the latter case. These results confirm
previous in vitro observations of the importance of local Ang
II in rats and humans.6,8 They are also in agreement with
recent studies that show that despite the fact that ACE is
present in the plasma of tissue ACE knockout mice, these
animals display the same hemodynamic and vascular abnor-
malities as mice that are completely ACE deficient.18,19 The
potencies obtained for Ang I and II in the present study were
in the nanomolar range, which is in agreement with the
known affinity of AT receptors for Ang II.20,21 It is therefore
unlikely that vasoconstriction during Ang I infusion was
mediated by Ang I.
In contrast with findings in isolated human blood ves-
sels,6,7,22 we did not obtain evidence for chymase-dependent
vasoconstriction in the human forearm. The ACE inhibitor
enalaprilat not only blocked forearm Ang I-to-II conversion
by .95% but also almost completely inhibited Ang I–in-
duced vasoconstriction. It is unlikely that the absence of a
chymase-mediated effect in the present study is due to the
inability of arterially infused Ang I to reach vascular chymase
(ie, to diffuse into the adventitia10). It has been previously
demonstrated that circulating Ang I and Ang II both rapidly
diffuse into the interstitial space.23,24 Furthermore, studies in
which the chymase-specific substrate [Pro11,D-Ala12]Ang I
was administered intravenously to marmosets or hamsters
showed clear dose-dependent pressor effects of this peptide
that could not be blocked with an ACE inhibitor.25,26 The
discrepancy between in vitro and in vivo studies with regard
to the importance of chymase might be due to the presence of
an endogenous chymase inhibitor, a1-antitrypsin, in intersti-
tial fluid.27 However, such in vivo chymase inhibition is not
in agreement with the vasoconstrictor effects obtained with
[Pro11,D-Ala12]Ang I.25,26 Moreover, a1-antitrypsin appeared
to inhibit chymase in tissue homogenates only,27,28 not in
intact preparations.6,28 A more likely explanation therefore is
disruption of mast cells during tissue storage or preparation,
which will result in chymase concentrations in vitro that are
far above those in vivo.
The forearm Ang I-to-II conversion rate obtained here is
in agreement with previous studies in which forearm
conversion was calculated during the infusion of 125I-
labeled Ang I.2 In those studies, the levels of 125I-Ang II
that were obtained at steady state were too low to induce
vasoconstriction. Remarkably, despite the clear dose-
dependent vasoconstriction that occurred in the present
study, fractional forearm Ang I-to-II conversion remained
constant at all FBF values. In contrast, fractional forearm
Ang I and II degradation correlated inversely with FBF.
This latter finding is not surprising, because at lower flow
rates, more time is available for metabolism. The fact that
Ang I-to-II conversion was not related to FBF suggests that
(1) it is a highly efficient process with a maximal result
even at high flow rates and (2) conversion most likely
precedes degradation (ie, that ACE might be located
predominantly in the arterioles).
In the present study, losartan, a competitive AT1 receptor
antagonist,29 fully prevented vasoconstriction at the 2 lowest
Ang II doses and in large part (.70%) inhibited vasocon-
striction at the highest dose of Ang II. These data are in
agreement with the contention that Ang II induces vasocon-
striction in the human forearm through the activation of AT1
receptors.
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